Moreover, it was demonstrated that CDK4/6 pathway is correlated to a potential resistance mechanism to anti-PD1 therapy in melanoma (48) and increased activity of the CDK4/6 inhibitor CDKN2A correlates with response to PD-L1 blockage in RCC and NSCLC patients (46). The gene discussed is CDK4; the disease is melanoma.